Literature DB >> 2753814

Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I.

M D Lee1, J K Manning, D R Williams, N A Kuck, R T Testa, D B Borders.   

Abstract

Novel antitumor antibiotics, calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I were recovered from the fermentation broth of Micromonospora echinospora ssp. calichensis by solvent extraction, selective precipitation, normal phase, reversed phase and partition chromatography. The individual components were characterized by their UV, IR, 1H and 13C NMR spectral data.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2753814     DOI: 10.7164/antibiotics.42.1070

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  14 in total

1.  Mutations in the P1 promoter region of Micromonospora echinospora.

Authors:  L S Lin; D M Rothstein
Journal:  J Bacteriol       Date:  1992-05       Impact factor: 3.490

2.  Isolation of mutants blocked in calicheamicin biosynthesis.

Authors:  D M Rothstein; S F Love
Journal:  J Bacteriol       Date:  1991-12       Impact factor: 3.490

3.  Conditions for protoplasting, regenerating, and transforming the calicheamicin producer, Micromonospora echinospora.

Authors:  S F Love; W M Maiese; D M Rothstein
Journal:  Appl Environ Microbiol       Date:  1992-04       Impact factor: 4.792

Review 4.  A comprehensive review of glycosylated bacterial natural products.

Authors:  Sherif I Elshahawi; Khaled A Shaaban; Madan K Kharel; Jon S Thorson
Journal:  Chem Soc Rev       Date:  2015-11-07       Impact factor: 54.564

5.  Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

Authors:  Luis Fayad; Fritz Offner; Mitchell R Smith; Gregor Verhoef; Peter Johnson; Jonathan L Kaufman; Ama Rohatiner; Anjali Advani; James Foran; Georg Hess; Bertrand Coiffier; Myron Czuczman; Eva Giné; Simon Durrant; Michelle Kneissl; Kenneth T Luu; Steven Y Hua; Joseph Boni; Erik Vandendries; Nam H Dang
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

Review 6.  Cancer nanomedicines: so many papers and so few drugs!

Authors:  Vincent J Venditto; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

7.  Crowdsourcing natural products discovery to access uncharted dimensions of fungal metabolite diversity.

Authors:  Lin Du; Andrew J Robles; Jarrod B King; Douglas R Powell; Andrew N Miller; Susan L Mooberry; Robert H Cichewicz
Journal:  Angew Chem Int Ed Engl       Date:  2013-11-27       Impact factor: 15.336

8.  Inspirations, discoveries, and future perspectives in total synthesis.

Authors:  K C Nicolaou
Journal:  J Org Chem       Date:  2009-02-06       Impact factor: 4.354

Review 9.  Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.

Authors:  Helen Ma; Ahmed Sawas
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

10.  Structure-guided functional characterization of enediyne self-sacrifice resistance proteins, CalU16 and CalU19.

Authors:  Sherif I Elshahawi; Theresa A Ramelot; Jayaraman Seetharaman; Jing Chen; Shanteri Singh; Yunhuang Yang; Kari Pederson; Madan K Kharel; Rong Xiao; Scott Lew; Ragothaman M Yennamalli; Mitchell D Miller; Fengbin Wang; Liang Tong; Gaetano T Montelione; Michael A Kennedy; Craig A Bingman; Haining Zhu; George N Phillips; Jon S Thorson
Journal:  ACS Chem Biol       Date:  2014-08-13       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.